Pharmacologically, SGLT2 inhibitors could be beneficial in MI by inhibiting the inflammatory pathways, modification of myocardial signal transduction through inhibition of Na + /H + exchanger, and metabolic effects [7]. Here, SLC5A2 is linked to myocardial infarction.